Structural Context of Disease-Associated Mutations and Putative Mechanism of Autoinhibition Revealed by X-Ray Crystallographic Analysis of the EZH2-SET Domain
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The enhancer-of-zeste homolog 2 (EZH2) gene product is an 87 kDa polycomb group (PcG) protein containing a C-terminal methyltransferase SET domain. EZH2, along with binding partners, i.e., EED and SUZ12, upon which it is dependent for activity forms the core of the polycomb repressive complex 2 (PRC2). PRC2 regulates gene silencing by catalyzing the methylation of histone H3 at lysine 27. Both overexpression and mutation of EZH2 are associated with the incidence and aggressiveness of various cancers. The novel crystal structure of the SET domain was determined in order to understand disease-associated EZH2 mutations and derive an explanation for its inactivity independent of complex formation. The 2.00 Å crystal structure reveals that, in its uncomplexed form, the EZH2 C-terminus folds back into the active site blocking engagement with substrate. Furthermore, the S-adenosyl-L-methionine (SAM) binding pocket observed in the crystal structure of homologous SET domains is notably absent. This suggests that a conformational change in the EZH2 SET domain, dependent upon complex formation, must take place for cofactor and substrate binding activities to be recapitulated. In addition, the data provide a structural context for clinically significant mutations found in the EZH2 SET domain.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353 · cited 1×
“The model building was done with COOT [52], and the structure refined with Refmac [53,54].”
MethodRole of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
McCabe, M. T., Ott, H. M., Ganji, G., Korenchuk, S., Thompson, C., Van Aller, G. S., Liu, Y., Graves, A. P., III, A. D. P., Diaz, E., et al. (2012) · Nature · doi:10.1038/nature11606 · Cited by 1,786
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Morin, R. D., Mendez-Lago, M., Mungall, A. J., Goya, R., Mungall, K. L., Corbett, R. D., Johnson, N. A., Severson, T. M., Chiu, R., Field, M., et al. (2011) · Nature · doi:10.1038/nature10351 · Cited by 1,614 · cited 5×
“Mutations of A682, a buried residue found at the terminus of β-6, have been identified in cases of lymphoma (A>G)[27,33], WS with neuroblastoma (A>T)[21], and AML (A>V)[29].”
BackgroundInfluentialThe genetic basis of early T-cell precursor acute lymphoblastic leukaemia
Zhang, J., Ding, L., Holmfeldt, L., Wu, G., Heatley, S. L., Payne-Turner, D., Easton, J., Chen, X., Wang, J., Rusch, M., et al. (2012) · Nature · doi:10.1038/nature10725 · Cited by 1,596
Kuzmichev, A., Nishioka, K., Erdjument-Bromage, H., Tempst, P., & Reinberg, D. (2002) · Genes & Development · doi:10.1101/gad.1035902 · Cited by 1,596 · cited 8×
“Mutation of EZH2 residue Y646 was found in 7% of follicular lymphoma cases [24] and 22% of diffuse large cell B-cell lymphomas and was coincident with increased H3K27 trimethylation.”
BackgroundInfluentialInactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · cited 8×
“Another mutation (C576W) was identified in a case of MDS [20] and disrupts coordination of zinc by cysteine in the second zinc binding domain also likely having a strong destabilization effect (Figure 8).”
BackgroundInfluentialA selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells
Knutson, S. K., Wigle, T. J., Warholic, N. M., Sneeringer, C. J., Allain, C. J., Klaus, C. R., Sacks, J. D., Raimondi, A., Majer, C. R., Song, J., et al. (2012) · Nature Chemical Biology · doi:10.1038/nchembio.1084 · Cited by 776 · cited 2×
“Due to the clearly established correlation between EZH2 function and numerous clinical syndromes, significant effort has been expended on the identification and development of specific small molecule inhibitors of the EZH2 methyltransferase activity [47-49].”
BackgroundStock, J. K., Giadrossi, S., Casanova, M., Brookes, E., Vidal, M., Koseki, H., Brockdorff, N., Fisher, A. G., & Pombo, A. (2007) · Nature Cell Biology · doi:10.1038/ncb1663 · Cited by 650 · cited 1×
“The PRC complexes repress gene expression through the SAM-catalyzed methylation of histone 3 (H3) proteins at lysine 27 (H3K27) [6] as well as other mechanisms [7,8].”
BackgroundStructural Biology of Human H3K9 Methyltransferases
Wu, H., Min, J., Lunin, V. V., Antoshenko, T., Dombrovski, L., Zeng, H., Allali-Hassani, A., Campagna-Slater, V., Vedadi, M., Arrowsmith, C. H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0008570 · Cited by 268 · cited 4×
“We determined the crystal structure of the isolated EZH2 SET domain in order to compare and contrast it with the crystal structure of other SET domains [50], better understand the structural context of clinically relevant EZH2 mutations, and to possibly elucidate autoregulatory mechanisms of EZH2 methyltransferase act…”
BackgroundResultInfluentialNovel homo- and hemizygous mutations in EZH2 in myeloid malignancies
Makishima, H., Jankowska, A. M., Tiu, R. V., Szpurka, H., Sugimoto, Y., Hu, Z., Saunthararajah, Y., Guinta, K., Keddache, M. A., Putnam, P., et al. (2010) · Leukemia · doi:10.1038/leu.2010.167 · Cited by 179 · cited 5×
“Mutations at positions A692 {(DLBCL) (A>V) [23,33]}, N693 {(AMML) (N>T) [18]; (ETP ALL) (N>Y) [26]; (MF) (N>Y) [31]}, and H694 {(WS) (H>Y) [22]; (CMML) (H>R) [18]} have been found in association with numerous diseases.”
BackgroundInfluentialPoint Mutations in the WD40 Domain of Eed Block Its Interaction with Ezh2
Denisenko, O., Shnyreva, M., Suzuki, H., & Bomsztyk, K. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.10.5634 · Cited by 98
Cited by
The molecular principles of gene regulation by Polycomb repressive complexes
Blackledge, N. P., & Klose, R. J. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00398-y · Cited by 476
Structural insights into conformational stability of both wild-type and mutant EZH2 receptor
Aier, I., Varadwaj, P. K., & Raj, U. (2016) · Scientific Reports · doi:10.1038/srep34984 · Cited by 431
Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2
Jiao, L., & Liu, X. (2015) · Science · doi:10.1126/science.aac4383 · Cited by 402
“The same set of residues may also direct H3K27 methylation when wild-type substrate is bound (15, 16, 31).”
BackgroundInfluentialYu, J.-R., Lee, C.-H., Oksuz, O., Stafford, J. M., & Reinberg, D. (2019) · Genes & Development · doi:10.1101/gad.325050.119 · Cited by 257
Mechanisms regulating PRC2 recruitment and enzymatic activity
Holoch, D., & Margueron, R. (2017) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2017.04.003 · Cited by 201
Metadata
- Authors
- Antonysamy, S., Condon, B., Druzina, Z., Bonanno, J. B., Gheyi, T., Zhang, F., MacEwan, I., Zhang, A., Ashok, S., Rodgers, L., Russell, M., & Gately Luz, J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-12-19
- Volume
- 8
- Issue
- 12
- Pages
- e84147
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2144488490
- Cited by
- 104
- References
- 12
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.